Recently, the Category 1 innovative drug Tunlametinib Capsules (Chinese trade name: 科露平) of Shanghai KeChow Pharma Inc. was approved with conditions through the priority review and approval procedure by China NMPA. It is indicated for patients with advanced NRAS-mutant melanoma who fail anti- PD-1/PD-L1 therapy.

　　Tunlametinib is a selective mitogen-activated protein kinase 1 and kinase 2 (MEK1/2) kinase inhibitor, which plays an antitumor role by inhibiting the activity of MEK1/2 kinase. The marketing of this drug provides new treatment options for patients with advanced NRAS-mutant melanoma who fail anti- PD-1/PD-L1 therapy.